Stocks / AKTS vs BCAX

Aktis Oncology, Inc. (AKTS) vs Bicara Therapeutics Inc. (BCAX)

Aktis Oncology, Inc. and Bicara Therapeutics Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.

BCAX is the larger company ($1.4B vs $1.0B). On the fundamentals, AKTS has the stronger return on equity (43.6% vs -34.4%). Both carry 1 potential red flag in the filings. Full numbers below — the stronger figure on each row is in green.

AI verdict — AKTS vs BCAX, read from the filings

The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.

 Aktis Oncology, Inc. (AKTS)Bicara Therapeutics Inc. (BCAX)
Market cap$1.0B$1.4B
Revenue (latest FY)$6.50M$0
Net income (latest FY)$-63.73M$-137.95M
Revenue growth (5y CAGR)
Net margin-980.9%
Return on equity43.6%-34.4%
P/E ratio
Dividend yield
Profitable years (of last 10)00
Positive free cash flowNoNo

Performance — AKTS vs BCAX

Total returns from monthly split- and dividend-adjusted closes; 52-week range from the latest quote. Past performance is not a prediction.

 Aktis Oncology, Inc. (AKTS)Bicara Therapeutics Inc. (BCAX)
1-year return125.2%
3-year return
5-year return
10-year return
52-week range$14.72–$29.16$8.48–$24.25

Verify the comparison

Use the filing period and source shown by each tool before treating two figures as comparable.

Compare with another company:

See the full AKTS vs BCAX breakdown

Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.

Open AKTS's full financials →   Open BCAX's full financials →

More comparisons

Frequently asked questions

Which is bigger, AKTS or BCAX?

Bicara Therapeutics Inc. is larger by market capitalization — $1.4B versus $1.0B.

Which grows faster, AKTS or BCAX?

Five-year growth data is not available for both companies.

Where does this data come from?

All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.

Keep exploring

AKTS fundamentals → · BCAX fundamentals → · All 1,500+ companies → · Free screener →